Skip to main content
Xilio Therapeutics, Inc. logo

Xilio Therapeutics, Inc. — Investor Relations & Filings

Ticker · XLO ISIN · US98422T1007 US Professional, scientific and technical activities
Open in API
Filings indexed 321 across all filing types
Latest filing 2025-06-12 Director's Dealing
Country US United States of America
Listing US XLO

About Xilio Therapeutics, Inc.

https://xiliotx.com/

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing tumor-activated immuno-oncology (IO) therapies for cancer treatment. The company utilizes a proprietary, clinically validated platform to engineer biologics, including antibodies, masked bispecifics, and T cell engagers. These molecules are designed to be 'masked' or inactive in systemic circulation and become fully active only within the tumor microenvironment. This approach aims to concentrate the therapeutic effect precisely on the tumor, thereby minimizing systemic toxicity and improving the efficacy-to-toxicity ratio of potent immunotherapies. Xilio's pipeline consists of multiple clinical and preclinical programs designed to deliver powerful cancer treatments to a broader patient population.

Recent filings

Filing Released Lang Actions
Director's Dealing 2025
Director's Dealing
2025-06-12 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated June 10, 2025, reporting the results of the company's 2025 annual meeting of stockholders. It details the voting outcomes on director elections, amendments to the certificate of incorporation, and ratification of the independent auditor. The content focuses on the submission of matters to a vote of security holders and the official voting results. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). The document is not a full annual report, audit report, or management report, but specifically an official announcement of shareholder voting results at the AGM. The length and detail support this classification with high confidence.
2025-06-12 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, dated June 10, 2025. The content focuses on the departure and election of a director to the Board of Directors, including details about the new director's term and committee appointment. There are no financial statements or detailed financial data presented. The primary subject is a change in the company's board composition, which aligns with announcements about board or management changes. Therefore, this document fits the category of Board/Management Information (MANG). The document length is under 5,000 characters and it is not an announcement of a report publication but a substantive filing about management changes.
2025-06-10 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Schedule 14A filing, which is a definitive proxy statement supplement related to the Annual Meeting of Stockholders. It includes detailed information about proxy solicitation, voting instructions, and amendments to the proxy materials. The text also references a Current Report on Form 8-K related to a material definitive agreement concerning an underwriting agreement for a public offering of warrants. The primary focus is on proxy materials and shareholder voting information, not on executive compensation details. Although the form name DEFA14A is similar to DEF 14A, which relates to remuneration information, this document is a proxy statement supplement, not a remuneration report. Therefore, the most appropriate classification is Proxy Solicitation & Information Statement (PSI). The document length (15,000 characters) and content confirm it is a full filing, not a brief announcement or certification.
2025-06-03 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content details the entry into a material definitive agreement related to an underwritten public offering of warrants and common stock, including terms, exercise prices, and conditions. This is a clear update on the company's capital raising activities and financing arrangements. It is not an annual or quarterly report, audit report, earnings release, or any other type of report. It is specifically an update on financing and capital structure changes. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence in this classification.
2025-06-03 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to an offering of pre-funded warrants and common stock warrants. It details the terms of the offering, underwriting, risk factors, and other related information. This type of document is a capital markets offering disclosure, specifically related to fundraising and securities issuance. It is not a financial report, earnings release, management discussion, or regulatory filing unrelated to capital raising. Therefore, it fits the category of Capital/Financing Update (CAP). The document length and content confirm it is the actual offering document, not just an announcement or a brief summary.
2025-06-03 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.